Brain-specific overexpression of trace amine-associated receptor 1 alters monoaminergic neurotransmission and decreases sensitivity to amphetamine

Neuropsychopharmacology

Volumn 37, Issue 12, 2012, Pages 2580-2592

  Revel, Florent G ^a   Meyer, Claas A ^a   Bradaia, Amyaouch ^b   Jeanneau, Karine ^a   Calcagno, Eleonora ^c   André, Cédric B ^a   Haenggi, Markus ^a,d   Miss, Marie Thérèse ^a   Galley, Guido ^a   Norcross, Roger D ^a   Invernizzi, Roberto W ^c   Wettstein, Joseph G ^a   Moreau, Jean Luc ^a   Hoener, Marius C ^a  

^a F HOFFMANN LA ROCHE LTD   (Switzerland)

^b Neuroservice   (France)

^c MARIO NEGRI INSTITUTE FOR PHARMACOLOGICAL RESEARCH   (Italy)

^d NOVARTIS PHARMA AG   (Switzerland)

Author keywords

amphetamine; partial agonist; TAAR1; trace amines; transgenic; VTA

Indexed keywords

6 CYANO 7 NITRO 2,3 QUINOXALINEDIONE; AMPHETAMINE; CATECHOLAMINE; DOPAMINE; MEMBRANE RECEPTOR; NORADRENALIN; PSYCHOSTIMULANT AGENT; RO 5073012; RO 5166017; RO 5212773; SEROTONIN; TRACE AMINE ASSOCIATED RECEPTOR 1; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; ATTENUATION; BEHAVIOR DISORDER; BRAIN; CATECHOLAMINE RELEASE; CONTROLLED STUDY; DORSAL RAPHE NUCLEUS; DRUG EFFICACY; DRUG SENSITIVITY; EXTRACELLULAR MATRIX; GENE EXPRESSION; GENE OVEREXPRESSION; IN VITRO STUDY; IN VIVO STUDY; LOCOMOTION; LOCUS CERULEUS; MALE; MAXIMUM PLASMA CONCENTRATION; MEDIAL PREFRONTAL CORTEX; MONOAMINE NERVE CELL; MONOAMINERGIC SYSTEM; MOUSE; NERVE CELL; NEUROTRANSMISSION; NONHUMAN; NUCLEUS ACCUMBENS; PREFRONTAL CORTEX; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN LOCALIZATION; RAT; SIGNAL TRANSDUCTION; TRANSGENIC MOUSE; VENTRAL TEGMENTUM;

AMPHETAMINE; ANILINE COMPOUNDS; ANIMALS; BEHAVIOR, ANIMAL; BIOGENIC MONOAMINES; BRAIN CHEMISTRY; CENTRAL NERVOUS SYSTEM STIMULANTS; DOPAMINERGIC NEURONS; ELECTROPHYSIOLOGICAL PHENOMENA; GAMMA-AMINOBUTYRIC ACID; IMIDAZOLES; MICE; MICE, INBRED C57BL; MICRODIALYSIS; MOTOR ACTIVITY; PATCH-CLAMP TECHNIQUES; PHENOTYPE; RECEPTORS, G-PROTEIN-COUPLED; SYNAPTIC TRANSMISSION; VENTRAL TEGMENTAL AREA;

EID: 84867582955     PISSN: 0893133X     EISSN: 1740634X     Source Type: Journal    
DOI: 10.1038/npp.2012.109     Document Type: Article

References (51)

1. Ardayfio PA, Leung A, Park J, Hwang DY, Moran-Gates T, Choi YK et al (2010). Pitx3-deficient aphakia mice display unique behavioral responses to psychostimulant and antipsychotic drugs. Neuroscience 166: 391-396.
2. Baumann MH, Char GU, De Costa BR, Rice KC, Rothman RB (1994). GBR12909 attenuates cocaine-induced activation of mesolimbic dopamine neurons in the rat. J Pharmacol Exp Ther 271: 1216-1222.
3. Beaulieu JM, Sotnikova TD, Marion S, Lefkowitz RJ, Gainetdinov RR, Caron MG (2005). An Akt/beta-arrestin 2/PP2A signaling complex mediates dopaminergic neurotransmission and behavior. Cell 122: 261-273.
4. Berry MD (2007). The potential of trace amines and their receptors for treating neurological and psychiatric diseases. Rev Recent Clin Trials 2: 3-19.
5. Borowsky B, Adham N, Jones KA, Raddatz R, Artymyshyn R, Ogozalek KL et al (2001). Trace amines: identification of a family of mammalian G protein-coupled receptors. Proc Natl Acad Sci U S A 98: 8966-8971.
6. Bradaia A, Berton F, Ferrari S, Luscher C (2005). beta-Arrestin2, interacting with phosphodiesterase 4, regulates synaptic release probability and presynaptic inhibition by opioids. Proc Natl Acad Sci U S A 102: 3034-3039.
7. Bradaia A, Trube G, Stalder H, Norcross RD, Ozmen L, Wettstein JG et al (2009). The selective antagonist EPPTB reveals TAAR1-mediated regulatory mechanisms in dopaminergic neurons of the mesolimbic system. Proc Natl Acad Sci U S A 106: 20081-20086.
8. Bunzow JR, Sonders MS, Arttamangkul S, Harrison LM, Zhang G, Quigley DI et al (2001). Amphetamine, 3,4-methylenedioxymethamphetamine, lysergic acid diethylamide, and metabolites of the catecholamine neurotransmitters are agonists of a rat trace amine receptor. Mol Pharmacol 60: 1181-1188.
9. Burchett SA, Hicks TP (2006). The mysterious trace amines: protean neuromodulators of synaptic transmission in mammalian brain. Prog Neurobiol 79: 223-246.
10. Calcagno E, Invernizzi RW (2010). Strain-dependent serotonin neuron feedback control: role of serotonin 2C receptors. J Neurochem 114: 1701-1710.
11. Caroni P (1997). Overexpression of growth-associated proteins in the neurons of adult transgenic mice. J Neurosci Methods 71: 3-9.
12. Dobi A, Margolis EB, Wang HL, Harvey BK, Morales M (2010). Glutamatergic and nonglutamatergic neurons of the ventral tegmental area establish local synaptic contacts with dopaminergic and nondopaminergic neurons. J Neurosci 30: 218-229.
13. Espinoza S, Salahpour A, Masri B, Sotnikova TD, Messa M, Barak LS et al (2011). Functional interaction between trace amineassociated receptor 1 and dopamine D2 receptor. Mol Pharmacol 80: 416-425.
14. Gaisler-Salomon I, Miller GM, Chuhma N, Lee S, Zhang H, Ghoddoussi F et al (2009). Glutaminase-deficient mice display hippocampal hypoactivity, insensitivity to pro-psychotic drugs and potentiated latent inhibition: relevance to schizophrenia. Neuropsychopharmacology 34: 2305-2322.
15. Geisler S, Derst C, Veh RW, Zahm DS (2007). Glutamatergic afferents of the ventral tegmental area in the rat. J Neurosci 27: 5730-5743.
16. Geracitano R, Federici M, Prisco S, Bernardi G, Mercuri NB (2004). Inhibitory effects of trace amines on rat midbrain dopaminergic neurons. Neuropharmacology 46: 807-814.
17. Grandy DK (2007). Trace amine-associated receptor 1-family archetype or iconoclast? Pharmacol Ther 116: 355-390.
18. Harris GC, Aston-Jones G (2003). Critical role for ventral tegmental glutamate in preference for a cocaine-conditioned environment. Neuropsychopharmacology 28: 73-76.
19. Hwang DY, Ardayfio P, Kang UJ, Semina EV, Kim KS (2003). Selective loss of dopaminergic neurons in the substantia nigra of Pitx3-deficient aphakia mice. Brain Res Mol Brain Res 114: 123-131.
20. Ittner LM, Gotz J (2007). Pronuclear injection for the production of transgenic mice. Nat Protoc 2: 1206-1215.
21. Lindemann L, Ebeling M, Kratochwil NA, Bunzow JR, Grandy DK, Hoener MC (2005). Trace amine-associated receptors form structurally and functionally distinct subfamilies of novel G protein-coupled receptors. Genomics 85: 372-385.
22. Lindemann L, Hoener MC (2005). A renaissance in trace amines inspired by a novel GPCR family. Trends Pharmacol Sci 26: 274-281.
23. Lindemann L, Meyer CA, Jeanneau K, Bradaia A, Ozmen L, Bluethmann H et al (2008). Trace amine-associated receptor 1 modulates dopaminergic activity. J Pharmacol Exp Ther 324: 948-956.
24. Luthi A, Van der Putten H, Botteri FM, Mansuy IM, Meins M, Frey U et al (1997). Endogenous serine protease inhibitor modulates epileptic activity and hippocampal long-term potentiation. J Neurosci 17: 4688-4699.
25. Marinelli M, Rudick CN, Hu XT, White FJ (2006). Excitability of dopamine neurons: modulation and physiological consequences. CNS Neurol Disord Drug Targets 5: 79-97.
26. Miller GM (2011). The emerging role of trace amine-associated receptor 1 in the functional regulation of monoamine transporters and dopaminergic activity. J Neurochem 116: 164-176.
27. Miller GM, Verrico CD, Jassen A, Konar M, Yang H, Panas H et al (2005). Primate trace amine receptor 1 modulation by the dopamine transporter. J Pharmacol Exp Ther 313: 983-994.
28. Nair-Roberts RG, Chatelain-Badie SD, Benson E, White-Cooper H, Bolam JP, Ungless MA (2008). Stereological estimates of dopaminergic, GABAergic and glutamatergic neurons in the ventral tegmental area, substantia nigra and retrorubral field in the rat. Neuroscience 152: 1024-1031.
29. Narang D, Tomlinson S, Holt A, Mousseau DD, Baker GB (2011). Trace amines and their relevance to psychiatry and neurology: a brief overview. Bull Clin Psychopharmacol 21: 73-79.
30. Nunes I, Tovmasian LT, Silva RM, Burke RE, Goff SP (2003). Pitx3 is required for development of substantia nigra dopaminergic neurons. Proc Natl Acad Sci U S A 100: 4245-4250.
31. Ramsey AJ, Laakso A, Cyr M, Sotnikova TD, Salahpour A, Medvedev IO et al (2008). Genetic NMDA receptor deficiency disrupts acute and chronic effects of cocaine but not amphetamine. Neuropsychopharmacology 33: 2701-2714.
32. Revel FG, Moreau JL, Gainetdinov RR, Bradaia A, Sotnikova TD, Mory R et al (2011). TAAR1 activation modulates monoaminergic neurotransmission, preventing hyperdopaminergic and hypoglutamatergic activity. Proc Natl Acad Sci U S A 108: 8485-8490.
33. Richards JG, Higgins GA, Ouagazzal AM, Ozmen L, Kew JN, Bohrmann B et al (2003). PS2APP transgenic mice, coexpressing hPS2mut and hAPPswe, show age-related cognitive deficits associated with discrete brain amyloid deposition and inflammation. J Neurosci 23: 8989-9003.
34. Rizzoli SO, Betz WJ (2005). Synaptic vesicle pools. Nat Rev Neurosci 6: 57-69.
35. Sesack SR, Carr DB (2002). Selective prefrontal cortex inputs to dopamine cells: implications for schizophrenia. Physiol Behav 77: 513-517.
36. Sesack SR, Grace AA (2010). Cortico-Basal Ganglia reward network: microcircuitry. Neuropsychopharmacology 35: 27-47.
37. Sotnikova TD, Beaulieu JM, Espinoza S, Masri B, Zhang X, Salahpour A et al (2010). The dopamine metabolite 3-methoxytyramine is a neuromodulator. PLoS One 5: e13452.
38. Sotnikova TD, Caron MG, Gainetdinov RR (2009). Trace amineassociated receptors as emerging therapeutic targets. Mol Pharmacol 76: 229-235.
39. Stalder H, Hoener MC, Norcross RD (2011). Selective antagonists of mouse trace amine-associated receptor 1 (mTAAR1): discovery of EPPTB (RO5212773). Bioorg Med Chem Lett 21: 1227-1231.
40. Torres GE, Gainetdinov RR, Caron MG (2003). Plasma membrane monoamine transporters: structure, regulation and function. Nat Rev Neurosci 4: 13-25.
41. Tzschentke TM (2001). Pharmacology and behavioral pharmacology of the mesocortical dopamine system. Prog Neurobiol 63: 241-320.
42. Vallender EJ, Xie Z, Westmoreland SV, Miller GM (2010). Functional evolution of the trace amine associated receptors in mammals and the loss of TAAR1 in dogs. BMC Evol Biol 10: 51.
43. van den Munckhof P, Luk KC, Ste-Marie L, Montgomery J, Blanchet PJ, Sadikot AF et al (2003). Pitx3 is required for motor activity and for survival of a subset of midbrain dopaminergic neurons. Development 130: 2535-2542.
44. Wolinsky TD, Swanson CJ, Smith KE, Zhong H, Borowsky B, Seeman P et al (2007). The Trace Amine 1 receptor knockout mouse: an animal model with relevance to schizophrenia. Genes Brain Behav 6: 628-639.
45. Xie Z, Miller GM (2007). Trace amine-associated receptor 1 is a modulator of the dopamine transporter. J Pharmacol Exp Ther 321: 128-136.
46. Xie Z, Miller GM (2008). Beta-phenylethylamine alters monoamine transporter function via trace amine-associated receptor 1: implication for modulatory roles of trace amines in brain. J Pharmacol Exp Ther 325: 617-628.
47. Xie Z, Miller GM (2009). A receptor mechanism for methamphetamine action in dopamine transporter regulation in brain. J Pharmacol Exp Ther 330: 316-325.
48. Xie Z, Westmoreland SV, Bahn ME, Chen GL, Yang H, Vallender EJ et al (2007). Rhesus monkey trace amine-associated receptor 1 signaling: enhancement by monoamine transporters and attenuation by the D2 autoreceptor in vitro. J Pharmacol Exp Ther 321: 116-127.
49. Xie Z, Westmoreland SV, Miller GM (2008). Modulation of monoamine transporters by common biogenic amines via trace amine-associated receptor 1 and monoamine autoreceptors in human embryonic kidney 293 cells and brain synaptosomes. J Pharmacol Exp Ther 325: 629-640.
50. Yamaguchi T, Sheen W, Morales M (2007). Glutamatergic neurons are present in the rat ventral tegmental area. Eur J Neurosci 25: 106-118.
51. Yamaguchi T, Wang HL, Li X, Ng TH, Morales M (2011). Mesocorticolimbic glutamatergic pathway. J Neurosci 31: 8476-8490.